This forum is for the discussion of anything to do with Prostate Cancer. There are only four rules:
No fundraisers, no commercials (although it is OK to recommend choices of treatment or medical people based on your personal research; invitations to participate in third-party surveys are also acceptable, provided there is no compensation to YANA);
No harvesting e-mail addresses for Spam;
No insults or flaming - be polite and respectful at all times and understand that there may be a variety of points of view, all of which may have some validity;
Opinions are OK, but please provide as much factual evidence as possible for any assertions that you are making
Failure to abide by these simple rules will result in the immediate and permanent suspension of your posting privileges.
Since this is an International Forum, please specify your location in your post.
My Husband has been offered on the good old NHS in the U.K. a new drug trial to commence in about 2 to 3 months time. His oncologist has told us that it is a trial for men who have locally advanced prostate cancer that doesn't show any mets on bone and Cat scans as yet but where their PSA is rising after Hormone therapy has become inefficient. To qualify they have to not have had any radiotherapy.
The drug is called ARAMIS. Any one heard about it or is on it.
The trial is to determine the effacy of Aramis, which seeks to block Androgen (male hormone, which is thought to fuel the PCa fire) reception at a cellular level. Basically a more cell directed androgen blockade. Essentially the research team will be looking at the time to development of metastases. The research is looking to extend that time.